SCHEMBL22833539

SCHEMBL22833539

COC(=O)CN1C(=O)COCC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AOC2 O75106 1/20 0.39
LMNA P02545 1/20 0.36
KDM4E B2RXH2 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
BRD4 O60885 1/20 0.33
KAT2B Q92831 1/20 0.32
KMT2A Q03164 3/20 0.31
ALDH1A1 P00352 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
POLB P06746 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
TP53 P04637 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24925203 0.81 AOC2 (0.38) AOC2KDM4ESMN1; SMN2KMT2APOLB
SCHEMBL22833643 0.76 LMNA (0.39) AOC2LMNAKDM4ESMN1; SMN2BRD4
SCHEMBL27398852 0.74 AOC2 (0.37) AOC2
SCHEMBL11724781 0.69 KDM4E (0.42) LMNAKDM4ESMN1; SMN2KAT2BKMT2A
SCHEMBL24879866 0.68 SMN1; SMN2 (0.41) AOC2KDM4ESMN1; SMN2BRD4KMT2A
SCHEMBL22833645 0.66 SMN1; SMN2 (0.37) LMNAKDM4ESMN1; SMN2BRD4KAT2B
SCHEMBL22833754 0.66 BRD4 (0.36) LMNAKDM4ESMN1; SMN2BRD4KAT2B
SCHEMBL22833603 0.66 LMNA (0.36) LMNAKDM4ESMN1; SMN2BRD4KAT2B
SCHEMBL2072995 0.64 ALDH1A1 (0.41) LMNAKDM4ESMN1; SMN2KMT2AALDH1A1
SCHEMBL17146975 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230014226-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2023-01-19 US disclosed
US-20230014226-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2023-01-19 US disclosed
EP-3986559-A1 NEW COMPOUNDS AND METHODS BenevolentAI Bio Limited (GB) 2022-04-27 EP disclosed
CN-114340734-A Novel compounds and methods 博善人工智能生物科技有限公司 2022-04-12 CN disclosed
WO-2020260871-A1 NEW COMPOUNDS AND METHODS BENEVOLENTAI BIO LIMITED (GB) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014226-A1 NEW COMPOUNDS AND METHODS ABL2, ABL1, ALK AOC2 2149/4885LMNA 1857/4885KDM4E 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.